MX2021002299A - Anticuerpos de anti-cd33 y metodos para usarlos. - Google Patents
Anticuerpos de anti-cd33 y metodos para usarlos.Info
- Publication number
- MX2021002299A MX2021002299A MX2021002299A MX2021002299A MX2021002299A MX 2021002299 A MX2021002299 A MX 2021002299A MX 2021002299 A MX2021002299 A MX 2021002299A MX 2021002299 A MX2021002299 A MX 2021002299A MX 2021002299 A MX2021002299 A MX 2021002299A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- methods
- compositions
- monoclonal
- mammalian
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
La presente descripción se dirige, en líneas generales, a composiciones que incluyen anticuerpos, por ejemplo, anticuerpos monoclonales, fragmentos de anticuerpos, etc., que se unen específicamente a un polipéptido CD33, por ejemplo, una CD33 de mamífero o CD33 humana, y el uso de estas composiciones para prevenir, reducir el riesgo o tratar a un individuo que lo necesite.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862726053P | 2018-08-31 | 2018-08-31 | |
PCT/US2019/048994 WO2020047374A1 (en) | 2018-08-31 | 2019-08-30 | Anti-cd33 antibodies and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021002299A true MX2021002299A (es) | 2021-04-28 |
Family
ID=67957407
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021002299A MX2021002299A (es) | 2018-08-31 | 2019-08-30 | Anticuerpos de anti-cd33 y metodos para usarlos. |
Country Status (22)
Country | Link |
---|---|
US (1) | US20210317208A1 (es) |
EP (1) | EP3843851A1 (es) |
JP (1) | JP2021534797A (es) |
KR (1) | KR20210070986A (es) |
CN (2) | CN113801229A (es) |
AR (1) | AR119259A1 (es) |
AU (1) | AU2019331018A1 (es) |
BR (1) | BR112021003016A2 (es) |
CA (1) | CA3108808A1 (es) |
CL (1) | CL2021000501A1 (es) |
CO (1) | CO2021003078A2 (es) |
CR (1) | CR20210155A (es) |
EA (1) | EA202190235A1 (es) |
EC (1) | ECSP21022299A (es) |
IL (1) | IL281008A (es) |
MA (1) | MA53492A (es) |
MX (1) | MX2021002299A (es) |
PE (1) | PE20211096A1 (es) |
PH (1) | PH12021550332A1 (es) |
SG (1) | SG11202101552SA (es) |
TW (1) | TW202016307A (es) |
WO (1) | WO2020047374A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JOP20190248A1 (ar) | 2017-04-21 | 2019-10-20 | Amgen Inc | بروتينات ربط مولد ضد trem2 واستخداماته |
EP3589658A1 (en) | 2017-08-03 | 2020-01-08 | Alector LLC | Anti-cd33 antibodies and methods of use thereof |
WO2023081898A1 (en) | 2021-11-08 | 2023-05-11 | Alector Llc | Soluble cd33 as a biomarker for anti-cd33 efficacy |
CN115724959B (zh) * | 2022-11-11 | 2023-06-20 | 杭州华葵金配生物科技有限公司 | 靶向甲型流感病毒核蛋白的抗体及其应用 |
Family Cites Families (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8124A (en) | 1851-05-27 | mcfarlan | ||
US982A (en) | 1838-10-16 | Stove fob -warming and cooking | ||
US5730A (en) | 1848-08-22 | Improvement in steam cotton-presses | ||
US69A (en) | 1836-10-27 | Machine eor picking or breaking wool and ginned or seedless cotton | ||
US4657760A (en) | 1979-03-20 | 1987-04-14 | Ortho Pharmaceutical Corporation | Methods and compositions using monoclonal antibody to human T cells |
US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
CA1338518C (en) | 1987-09-23 | 1996-08-13 | Joyce M. Zarling | Antibody heteroconjugates for the killing of hiv-infected cells |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
EP0368684B2 (en) | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
ES2096590T3 (es) | 1989-06-29 | 1997-03-16 | Medarex Inc | Reactivos biespecificos para la terapia del sida. |
US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
EP0504327B1 (en) | 1989-12-14 | 2000-09-20 | Sloan-Kettering Institute For Cancer Research | Therapeutic uses of the hypervariable region of monoclonal antibody m195 and constructs thereof |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
WO1992000373A1 (en) | 1990-06-29 | 1992-01-09 | Biosource Genetics Corporation | Melanin production by transformed microorganisms |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
EP0546073B1 (en) | 1990-08-29 | 1997-09-10 | GenPharm International, Inc. | production and use of transgenic non-human animals capable of producing heterologous antibodies |
DK0564531T3 (da) | 1990-12-03 | 1998-09-28 | Genentech Inc | Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
LU91067I2 (fr) | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
CA2116774C (en) | 1991-09-19 | 2003-11-11 | Paul J. Carter | Expression in e. coli antibody fragments having at least a cysteine present as a free thiol. use for the production of bifunctional f(ab') 2 antibodies |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
US5766886A (en) | 1991-12-13 | 1998-06-16 | Xoma Corporation | Modified antibody variable domains |
US5869619A (en) | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
CA2372813A1 (en) | 1992-02-06 | 1993-08-19 | L.L. Houston | Biosynthetic binding protein for cancer marker |
ZA932523B (en) | 1992-04-10 | 1994-10-08 | Res Dev Foundation | Immunotoxins directed against cd33 related surface antigens |
DE69308573T2 (de) | 1992-08-17 | 1997-08-07 | Genentech Inc | Bispezifische immunoadhesine |
US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
JP2002514895A (ja) | 1995-09-28 | 2002-05-21 | アレクション、ファーマスーティカルズ、インコーポレーテッド | ブタ細胞相互作用タンパク質 |
US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
IL136544A0 (en) | 1997-12-05 | 2001-06-14 | Scripps Research Inst | Humanization of murine antibody |
GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
MXPA02003456A (es) | 1999-10-04 | 2002-10-23 | Medicago Inc | Metodo para regular la transcripcion de genes foraneos. |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
DE60131456T2 (de) | 2000-11-30 | 2008-07-10 | Medarex, Inc., Milpitas | Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern |
US20030206916A1 (en) | 2002-05-03 | 2003-11-06 | Rush-Presbyterian-St. Luke's Medical Center | Immunogenic peptides |
DK1578446T3 (en) | 2002-11-07 | 2015-06-29 | Immunogen Inc | ANTI-CD33 ANTIBODIES AND PROCEDURES FOR TREATING ACUTE MYELOID LEUKEMIA BY USING IT |
CN1961003B (zh) | 2004-03-31 | 2013-03-27 | 健泰科生物技术公司 | 人源化抗TGF-β抗体 |
US7700099B2 (en) | 2005-02-14 | 2010-04-20 | Merck & Co., Inc. | Non-immunostimulatory antibody and compositions containing the same |
TW200726776A (en) | 2005-07-29 | 2007-07-16 | Friedrich Alexander University Of Erlangen Nuremberg | CD33-specific single-chain immunotoxin and methods of use |
PT2359834T (pt) | 2006-03-15 | 2016-12-23 | Alexion Pharma Inc | Tratamento de doentes com hemoglobimúria paroxística noturna por meio de um inibidor de complemento |
EP2016101A2 (en) | 2006-05-09 | 2009-01-21 | Genentech, Inc. | Binding polypeptides with optimized scaffolds |
WO2008058021A2 (en) | 2006-11-02 | 2008-05-15 | Seattle Genetics, Inc. | Methods of treating neoplastic, autoimmune and inflammatory diseases |
UY30776A1 (es) | 2006-12-21 | 2008-07-03 | Medarex Inc | Anticuerpos cd44 |
CN100592373C (zh) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | 液晶显示面板驱动装置及其驱动方法 |
FR2945538B1 (fr) | 2009-05-12 | 2014-12-26 | Sanofi Aventis | Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide. |
DE102009045006A1 (de) | 2009-09-25 | 2011-04-14 | Technische Universität Dresden | Anti-CD33 Antikörper und ihre Anwendung zum Immunotargeting bei der Behandlung von CD33-assoziierten Erkrankungen |
WO2011038301A2 (en) | 2009-09-25 | 2011-03-31 | Xoma Technology Ltd. | Screening methods |
UA112062C2 (uk) | 2010-10-04 | 2016-07-25 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Cd33-зв'язувальний агент |
WO2012074097A1 (ja) | 2010-12-03 | 2012-06-07 | 協和発酵キリン株式会社 | 抗cd33抗体 |
US20130309223A1 (en) * | 2012-05-18 | 2013-11-21 | Seattle Genetics, Inc. | CD33 Antibodies And Use Of Same To Treat Cancer |
JP2018518491A (ja) | 2015-06-12 | 2018-07-12 | アレクトル エルエルシー | 抗cd33抗体及びその使用方法 |
AU2016276981B2 (en) | 2015-06-12 | 2022-10-06 | Alector Llc | Anti-CD33 antibodies and methods of use thereof |
-
2019
- 2019-08-30 JP JP2021511561A patent/JP2021534797A/ja active Pending
- 2019-08-30 KR KR1020217009223A patent/KR20210070986A/ko active Search and Examination
- 2019-08-30 TW TW108131323A patent/TW202016307A/zh unknown
- 2019-08-30 EA EA202190235A patent/EA202190235A1/ru unknown
- 2019-08-30 MA MA053492A patent/MA53492A/fr unknown
- 2019-08-30 PE PE2021000264A patent/PE20211096A1/es unknown
- 2019-08-30 MX MX2021002299A patent/MX2021002299A/es unknown
- 2019-08-30 CA CA3108808A patent/CA3108808A1/en active Pending
- 2019-08-30 AR ARP190102478A patent/AR119259A1/es unknown
- 2019-08-30 CN CN202110955735.XA patent/CN113801229A/zh active Pending
- 2019-08-30 CN CN201980070570.9A patent/CN112912144A/zh active Pending
- 2019-08-30 WO PCT/US2019/048994 patent/WO2020047374A1/en unknown
- 2019-08-30 BR BR112021003016-6A patent/BR112021003016A2/pt not_active Application Discontinuation
- 2019-08-30 SG SG11202101552SA patent/SG11202101552SA/en unknown
- 2019-08-30 AU AU2019331018A patent/AU2019331018A1/en not_active Abandoned
- 2019-08-30 US US17/272,083 patent/US20210317208A1/en active Pending
- 2019-08-30 EP EP19769302.1A patent/EP3843851A1/en active Pending
- 2019-08-30 CR CR20210155A patent/CR20210155A/es unknown
-
2021
- 2021-02-16 PH PH12021550332A patent/PH12021550332A1/en unknown
- 2021-02-21 IL IL281008A patent/IL281008A/en unknown
- 2021-02-26 CL CL2021000501A patent/CL2021000501A1/es unknown
- 2021-03-09 CO CONC2021/0003078A patent/CO2021003078A2/es unknown
- 2021-03-30 EC ECSENADI202122299A patent/ECSP21022299A/es unknown
Also Published As
Publication number | Publication date |
---|---|
PH12021550332A1 (en) | 2021-10-04 |
US20210317208A1 (en) | 2021-10-14 |
KR20210070986A (ko) | 2021-06-15 |
ECSP21022299A (es) | 2021-04-29 |
CA3108808A1 (en) | 2020-03-05 |
CN113801229A (zh) | 2021-12-17 |
JP2021534797A (ja) | 2021-12-16 |
AU2019331018A1 (en) | 2021-03-11 |
TW202016307A (zh) | 2020-05-01 |
PE20211096A1 (es) | 2021-06-14 |
CO2021003078A2 (es) | 2021-03-19 |
CR20210155A (es) | 2021-05-10 |
EP3843851A1 (en) | 2021-07-07 |
BR112021003016A2 (pt) | 2021-05-18 |
MA53492A (fr) | 2021-09-15 |
CL2021000501A1 (es) | 2021-07-23 |
SG11202101552SA (en) | 2021-03-30 |
IL281008A (en) | 2021-04-29 |
WO2020047374A1 (en) | 2020-03-05 |
AR119259A1 (es) | 2021-12-09 |
CN112912144A (zh) | 2021-06-04 |
EA202190235A1 (ru) | 2021-07-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020011828A (es) | Anticuerpos anti proteina alfa reguladora de se?ales (sirpa) y metodos de uso de los mismos. | |
CR20230169A (es) | ANTICUERPOS ANTI-TREM2 Y MÉTODOS PARA UTILIZARLOS (divisional 2019-0485) | |
PH12019502463A1 (en) | Anti-cd33 antibodies and methods of use thereof | |
WO2016201389A3 (en) | Anti-cd33 antibodies and methods of use thereof | |
WO2016201388A3 (en) | Anti-cd33 antibodies and methods of use thereof | |
MX2017012802A (es) | Anticuerpos antisortilina y métodos para su uso. | |
WO2017075432A3 (en) | Anti-siglec-9 antibodies and methods of use thereof | |
WO2017062672A3 (en) | Anti-trem2 antibodies and methods of use thereof | |
WO2017152102A3 (en) | Anti-trem1 antibodies and methods of use thereof | |
MX2020013324A (es) | Anticuerpos anti proteína reguladora de señales beta 1 (sirp-beta1) y métodos de uso de los mismos. | |
MX2021002299A (es) | Anticuerpos de anti-cd33 y metodos para usarlos. | |
CR20210057A (es) | Anticuerpos anti-sortilina y métodos para su uso | |
MX2022007231A (es) | Anticuerpos anti-mertk y metodos de uso de los mismos. | |
MX2021000933A (es) | Anticuerpos anti-siglec-5 y métodos para su uso. | |
CR20220078A (es) | Anticuerpos anti-ms4a4a y métodos de uso de los mismos | |
MX2020013172A (es) | Anticuerpos anti-siglec-7 y sus metodos de uso. | |
MX2022007156A (es) | Metodos de uso de anticuerpos anti-cd33. | |
EA201992324A1 (ru) | Анти-trem2 антитела и способы их применения | |
TW202415679A (zh) | 抗gpnmb抗體及其使用方法 |